The Food and Drug Administration (FDA) of the United States said that, it is now accepted the first generic version of the ABBV.N drug of the AbbVie for the purpose of increasing the production of tears in the patients suffering from the dry eye syndrome.
The condition, that is responsible for affecting the millions of people in the United States for around two decades, and this drug is going to be helping the people for making sufficient tears for the purpose of keeping their eyes wet and when the tears do not work properly that can possibly affect the production of tears.
The US FDA has also given authorization to the Viatris Inc, drug VTRS.O, and the company has been formed through the integration of the PFE.N off-patent drug business of the Pfizer Inc. and the generic drug producer known as Mylan Pharmaceuticals in the year 2020.
